Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

被引：0

作者：

Sehn, Laurie H. ^{[1
,2
]}

Luminari, Stefano ^{[3
,4
]}

Scholz, Christian W. ^{[5
]}

Huebel, Kai ^{[6
,7
,8
]}

Salar, Antonio ^{[9
]}

Paneesha, Shankara ^{[10
,11
]}

Wahlin, Bjorn E. ^{[12
]}

Panayiotidis, Panayiotis ^{[13
]}

Lee, Hui-Peng ^{[14
]}

Ubieto, Ana Jimenez ^{[15
]}

Sancho, Juan-Manuel ^{[16
]}

Kim, Tae Min ^{[17
]}

Domenech, Eva Domingo ^{[18
]}

Kumode, Takahiro ^{[19
]}

Poh, Christina ^{[20
]}

Thieblemont, Catherine ^{[21
]}

Deeren, Dries ^{[22
]}

de Wit, Edwin ^{[23
]}

Arbushites, Michael ^{[24
]}

Casadebaig, Marie-Laure ^{[23
]}

Trneny, Marek ^{[25
,26
]}

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Modena & Reggio Emilia, Oncol & Regenerat Med, Surg Med & Dent Morphol Sci Related Transplant, Reggio Emilia, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] Vivantes Klinikum Urban, Berlin, Germany

[6] Univ Cologne, Cologne, Germany

[7] Univ Hosp Cologne, Fac Med, Cologne, Germany

[8] Univ Hosp Cologne, Cologne, Germany

[9] Hosp Mar IMIM, Barcelona, Spain

[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[11] Univ Birmingham, Birmingham, England

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Natl & Kapodistrian Univ Athens, Gen Hosp LAIKO, Med Sch, Athens, Greece

[14] Flinders Med Ctr, Adelaide, Australia

[15] Hosp 12 Octubre, Serv Hematol, Madrid, Spain

[16] Univ Autonoma Bacrcelona, ICO IJC Hosp Germans Trias & Pujol, Barcelona, Spain

[17] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[18] Hosp Duran I Reynals, IDIBELL, Inst Catala Oncol, Barcelona, Spain

[19] Kindai Univ, Osaka, Japan

[20] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[21] St Paris Cite Univ, St Hosp, Assistance Publ Hop Paris, Paris, France

[22] AZ Delta Gen Hosp, Roeselare, Belgium

[23] Incyte Int Biosci, Sarl Morges, Switzerland

[24] Incyte Corp, Wilmington, DE USA

[25] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[26] Gen Hosp, Prague, Czech Republic

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-212970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA1 / LBA4

页数：4

共 50 条

[1] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
Sehn, Laurie Helen
Hubel, Kai
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe Marc
Paneesha, Shankara
Trneny, Marek
Mashegu, Hafsat Umar
Lihou, Christine Francis
Li, Di
Scholz, Christian W.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, Laurie H.
Hubel, Kai
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe
Paneesha, Shankara
Trneny, Marek
Mashegu, Hafsat
Lihou, Christine F.
Cheng, Lulu
Scholz, Christian W.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
[3] inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, Laurie H.
Scholz, Christian W.
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe
Trneny, Marek
Paneesha, Shankara
Manzke, Oliver
Seguy, Francis
Li, Di
Huebel, Kai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S402 - S402
[4] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Sehn, Laurie Helen
Scholz, Christian W.
Luminari, Stefano
Salar, Antonio
Wahlin, Bjorn E.
Gopal, Ajay K.
Bonnet, Christophe Marc
Paneesha, Shankara
Manzke, Oliver
Seguy, Francis
Li, Di
Huebel, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Della Cioppa, P.
Lucania, A.
Esposito, M.
Improta, S.
Mastrullo, L.
HAEMATOLOGICA, 2015, 100 : 151 - 151
[6] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Larsen, Thomas S.
Manzke, Oliver
Leibovitz, Daniel
Arbushites, Michael
BLOOD, 2022, 140 : 12077 - 12078
[7] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P.
Trneny, Marek
Izutsu, Koji
Fowler, Nathan H.
Hong, Xiaonan
Zhu, Jun
Zhang, Huilai
Offner, Fritz
Scheliga, Adriana
Nowakowski, Grzegorz S.
Pinto, Antonio
Re, Francesca
Fogliatto, Laura Maria
Scheinberg, Phillip
Flinn, Ian W.
Moreira, Claudia
Cabecadas, Jose
Liu, David
Kalambakas, Stacey
Fustier, Pierre
Wu, Chengqing
Gribben, John G.
Calaminici, Maria
Copie-Bergman, Christiane
Lopez-Guillermo, Armando
O'Connor, Owen
Williams, Michael
Suciu, Stefan
Levine, Benjamin
Kern, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
[8] Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results
Linton, Kim M.
Wahlin, Bjorn
Leppa, Sirpa
Morschhauser, Franck
Elliott, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 94 - 94
[9] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Falchi, Lorenzo
Abrisqueta, Pau
Nijland, Marcel
Leppa, Sirpa
Hutchings, Martin
Holte, Harald
Merryman, Reid W.
Lugtenburg, Pieternella
de Vos, Sven
Cheah, Chan Y.
Christensen, Jacob Haaber
Arcaini, Luca
Drott, Kristina
Hellstrom, Mats
Leslie, Lori A.
Vitolo, Umberto
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Belada, David
BLOOD, 2022, 140 : 1464 - 1466
[10] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
Salles, Gilles
Shah, Harsh
Leonard, John P.
Szanto, Attila
Chen, Jade
Bannerji, Rajat
Morschhauser, Franck
Nastoupil, Loretta J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455

← 1 2 3 4 5 →